Bostic J R, Brown K E, Young N S, Koenig S
MedImmune, Inc., Gaithersburg, MD 20878, USA.
J Infect Dis. 1999 Mar;179(3):619-26. doi: 10.1086/314648.
Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitative assay for parvovirus neutralization. A novel in vitro test for parvovirus neutralization has been developed using reverse transcriptase-polymerase chain reaction to detect viral transcripts in a B19-permissive cell line. Parvovirus neutralizing activity was measured in sera from naturally infected individuals, and common features of sera with high neutralizing capacity were identified as protection correlates. Sera that suppressed B19 replication in vitro demonstrated IgG reactivity with capsid proteins VP1 and VP2, but no linear relationship between antibody titer and neutralizing capacity was observed. Sera from experimental animals and human volunteers immunized with a virus-like particle vaccine candidate exhibited B19 neutralizing titers equal to or greater than those observed in natural infections.
人细小病毒B19感染可引发传染性红斑、急性和慢性红细胞再生障碍、胎儿水肿、关节病及其他病症。抗病毒抗体在体内限制B19感染；然而，由于缺乏细小病毒中和定量检测方法，保护的血清学标志物的鉴定受到阻碍。已开发出一种新型的细小病毒中和体外试验，利用逆转录聚合酶链反应检测B19允许细胞系中的病毒转录本。在自然感染个体的血清中测量细小病毒中和活性，并将具有高中和能力的血清的共同特征确定为保护相关因素。在体外抑制B19复制的血清表现出与衣壳蛋白VP1和VP2的IgG反应性，但未观察到抗体滴度与中和能力之间的线性关系。用候选病毒样颗粒疫苗免疫的实验动物和人类志愿者的血清表现出的B19中和滴度等于或高于自然感染中观察到的滴度。
